Expanded access to daraxonrasib signals ‘dawn of a new era’ in pancreatic cancer treatment

Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” After compelling data from a late-stage trial are presented at a major medical meeting or published in a peer-reviewed journal, excitement about a potentially practice-changing treatment spreads like wildfire through the clinical community and the findings support a